Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the "Company") and Phytanix Bio Inc. have entered into a definitive share exchange agreement pursuant to which the two entities will combine in an all-stock transaction (the "Combination"). The combined entity, to be called Phytanix, Inc., will bring together two pipelines focused on stress-related and CNS disorders, five preclinical assets and one clinical-stage asset.
Pipeline Assets
PT-00114 (Phase I/IIa): peptide asset in BLA pathway; may qualify for regulatory data exclusivity
PHYX-001: potassium channel modulator with mechanism similar to XEN1101 and BHV-7000
Cannabinoid Assets: multiple cannabinoid-based compounds with composition-of-matter IP; potential in CNS, cardiometabolic, and other indications. Including a proprietary molecule with significant potential in the obesity, metabolic dysfunction sector, where the GLP-1 agonists have become blockbuster medications
Modified Stilbenoid Assets: modified stilbenoid compounds with composition-of-matter IP and anticonvulsant activity in preclinical models
Key Benefits for Protagenic Shareholders
Pipeline Expansion: adds new CNS programs to existing stress-disorder portfolio
Pipeline Diversity: clinical- and preclinical-stage assets with potential significant milestones over the next 18 months
CNS Expertise: integrates Phytanix Bio team members who worked on Sativex® and Epidiolex® at GW Pharma
Patent Estate: broader composition-of-matter coverage across the pipeline
Talent Pool: combined teams to advance development and regulatory activities
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.